ACOG (alphacognition.com) EV/EBITDA Multiple
This price chart for Alpha Cognition (ACOG) demonstrates an EV/EBITDA ratio of 0.00. Alpha Cognition focuses on developing safer dementia treatments by minimizing adverse bodily reactions to capture a broad market segment. The business relies on a comprehensive system for combating Alzheimer's and the drug Alpha-1062. Furthermore, development is conducted within US jurisdiction, ensuring the stability of programs against external trade conflicts.
Summary analytical data breakdowns for alphacognition.com (ACOG)
- market price and analyst price targets:
- business market valuation indicators:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Capital Alpha Cognition|ACOG - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Alpha Cognition Inc.|ACOG - Company Cumulative Debt|Debts to Book Capitalization Alpha Cognition Inc.|ACOG - Long-Term Indebtedness|Company Short-Term Debt Alpha Cognition|Quick Ratio alphacognition.com
- financial results and valuation multiples details:
ACOG - Net Financial Result|Future Profit Alpha Cognition|ACOG - Market Price to Net Income Ratio|Forward P/E Multiple Alpha Cognition Inc.|ACOG - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alpha Cognition Inc.|ACOG - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Alpha Cognition|ACOG - Earnings per share for the last 12 months|Quarterly EPS earnings growth alphacognition.com|ACOG - Earnings growth in current year|Earnings growth forecast for next year Alpha Cognition
Initial company analysis:Alpha Cognition Corp ACOG
When constructing a long-term portfolio, fundamental screening requires accounting for the aggregate value of assets and liabilities. This indicator compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest. For Alpha Cognition (ACOG), which is developing an innovative drug for Alzheimer's disease, such a valuation is critical when scaling production. Analyzing the EV/EBITDA multiple trend helps determine whether the market price is fair relative to the company's growth potential.
Main competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|NBIX (Neurocrine Corp) - Company Value to Operating Income Before Depreciation Ratio|Regencell Bioscience - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation AXSM (axsome.com)|ACAD: EV/EBITDA Multiple|Xenon Pharmaceuticals Inc. (XENE) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio VKTX|SUPN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPRX|Enterprise Value to EBITDA Ratio denalitherapeutics.com DNLI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|Biohaven Ltd (BHVN) - Company Value to EBITDA|Amylyx - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Trevi Corp (TRVI)|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation AVXL|CBLL (CeriBell) - EV/EBITDA Multiple|Prothena Corporation PLC (PRTA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio ALEC (Alector, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ANNX|EV/EBITDA Multiple OMER (Omeros)|Total Company Value to Operating Income Before Depreciation Ratio neurogene.com (NGNE)|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Voyager Therapeutics Inc|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation SCLX|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|EV/EBITDA Multiple cogrx.com|EV/EBITDA Multiple IKT|Enterprise Value to EBITDA Ratio Cassava Sciences Inc SAVA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Assertio ASRT|Coya Therapeutics Inc (COYA) - Company Value to EBITDA|VistaGen Therapeutics Inc - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Ovid Therapeutics Inc. (OVID)|Acumen Pharmaceuticals, Inc. (ABOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CRVO|ATHE (Alterity Therapeutics Ltd.) - EV/EBITDA Multiple|Company Value to EBITDA Clene Nanomedicine CLNN|Enterprise Value to EBITDA Ratio PEPG (PepGen Inc.)|EV/EBITDA Multiple jupiterneurosciences.com (JUNS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|Business Value to Operating Income Before Depreciation ANVS|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Firefly Neuro|KLTO: EV/EBITDA Multiple|NeuroSense Therapeutics Ltd. (NRSN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MTVA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PASG (Passage Bio)|Business Value to Operating Income Before Depreciation NEUP|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|ATHA - EV/EBITDA Multiple|ADXN (Addex Therapeutics, Ltd.) - Enterprise Value to EBITDA Ratio|Alzamend Neuro - Business Value to Operating Income Before Depreciation|CYCN (Cyclerion Therapeutics Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Protagenic (PTIX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT - Company Value to EBITDA|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|Enterprise Value to EBITDA Multiple BrainStorm Cell Therapeutics Inc.|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CHRO (chromocell.com) - Enterprise Value to Operating Income Before Depreciation|ELYM: EV/EBITDA Multiple|ITCI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio LBPH|MRNS (Marinus Pharma) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NKGN|Total Company Value to Operating Income Before Depreciation Ratio neurobopharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|Synaptogenix Inc. (SNPX) - Company Value to EBITDA|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIGL (Vigil Neuroscience) - Enterprise Value to Operating Income Before Depreciation|WENA: EV/EBITDA Multiple|cerevel.com (CERE) - EV/EBITDA Multiple
